AUS
NZ
UK
CA
USA
IND
hVIVO PLC (LSE:HVO) CEO Yamin (Mo) Khan recently discussed the company’s notable achievements in the first half of 2024 with Proactive's Stephen Gunnion. During this period, hVIVO reported a 31% increase in revenue, reaching £35.6 million. Khan highlighted a record EBITDA of £8.7 million, marking a 68% year-on-year growth. These accomplishments are largely attributed to the inauguration of the world’s largest human challenge trial facility in Canary Wharf, which features 50 beds designed for CL3 level pathogen trials.
Khan also outlined hVIVO’s strategic expansion into new service areas beyond human challenge trials. This includes the enhancement of laboratory services and patient recruitment through the FluCamp platform. The company has a robust order book valued at £71 million and a sales pipeline with £40 million in potential opportunities, underscoring its strong market position.
Looking forward, hVIVO has reaffirmed its revenue guidance for 2024 at £62 million and anticipates an EBITDA margin at the higher end of market expectations. With a positive outlook for continued growth, hVIVO remains committed to achieving its 2028 revenue goal of £100 million. The company’s recent advancements and strategic initiatives are set to bolster its market presence and operational capabilities, positioning it for sustained success in the coming years.
